Bayer Among Investors In $12M Funding For Edifice’s OTC Test For ‘Inflammatory Age’
Bayer led a $12m investment in Edifice Health, which plans to launch an OTC test kit to measure “inflammatory age” to help prevent chronic diseases. Consumer health R&D head Dave Evendon-Challis says the investment is in line with focus on deals for “big innovation jumps” in prevention.
You may also be interested in...
The future of digital health will be shaped more than anything else by the rise of artificial intelligence. From body enhancing bio-wearables to camera-based skin diagnostics, the consumer health industry continued to explore the possibilities presented by AI in 2021. However, there are many regulatory and ethical hurdles industry must overcome as we move into 2022 and beyond.
“If the previous decade was about the new digital, the current decade will require brands to undergo dynamic transformation,” said creative media consultant Kate Scott-Dawkins at NAD conference.
Bayer says its Consumer Health sales grew at twice the rate of the market in Q3, thanks to a number of operational changes instituted by business head Heiko Schipper back in 2018.